Evidence map›Paper›PMID 29872620›Full record

ReviewActa pharmaceutica Sinica. B2018

Biomimetic nanoparticles for inflammation targeting.

Kai Jin, Zimiao Luo, Bo Zhang, Zhiqing Pang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kai JinSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.
Zimiao LuoSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.
Bo ZhangSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.
Zhiqing PangSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There have been many recent exciting developments in biomimetic nanoparticles for biomedical applications. Inflammation, a protective response involving immune cells, blood vessels, and molecular mediators directed against harmful stimuli, is closely associated with many human diseases. As a result, biomimetic nanoparticles mimicking immune cells can help achieve molecular imaging and precise drug delivery to these inflammatory sites. This review is focused on inflammation-targeting biomimetic nanoparticles and will provide an in-depth look at the design of these nanoparticles to maximize their benefits for disease diagnosis and treatment.

Indexed as

apoE–/– mice, Apolipoprotein e knockout miceBiomimetic nanoparticlesCAM, cellular adhesion moleculeCCL5, chemokine (C-C motif) ligand 5CD40L, cluster of differentiation 40 ligandCell membraneCell membrane proteinsCTC, circulating tumor cellCTL, cytotoxic T cell or CD8+ T cellCXCL4, chemokine (C-X-C motif) ligand 4CXCR1, chemokine (C-X-C motif) receptor 1Cy7, cyanine 7DC, dendritic cellDSPE-PEG, distearoyl Phosphoethanolamine-poly(ethylene glycol)GPIbα, glycoprotein IbαGPIV, glycoprotein IVGPIX, glycoprotein IXGPV, glycoprotein VGPVI, glycoprotein VIHUVEC, umbilical cord vascular endothelial cellIBD, inflammatory bowel diseaseICAM-1, intercellular cellular adhesion molecule-1IgG, immunoglobulin GIL, interleukinImmune cellsInflammation targetingLFA-1, lymphocyte function associated antigen-1LLV, leukocyte-like vectorLPS, lipopolysaccharideMac-1, macrophage adhesion molecule-1MHC, major histocompatibility complexMolecular imagingMRI, magnetic resonance imagingNM-NP, neutrophil membrane-coated nanoparticlePECAM-1, platelet-endothelial cellular adhesion molecule-1PLA-PEG, poly(lactic acid)-poly(ethylene glycol)PLGA, poly(lactic-co-glycolic acid)PNP, platelet membrane-cloaked nanoparticlePSGL-1, P-selectin glycoprotein ligand-1RA, rheumatoid arthritisRBC, red blood cellSLeX, sialyl lewis XSPIO, super paramagnetic iron oxideTargeting ligandsTGF-β, transforming growth factor βTh cell, T-helper cell or CD4+ T cellTNF-α, tumor necrosis factor-αVCAM-1, vascular cellular adhesion molecule-1VLA-4, very late antigen-4VWF, Von Willebrand factor

Identifiers

PMID29872620
PMCPMC5985691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.